Clinical Trials | Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer

The University of Virginia Comprehensive Cancer Center seeks participants ages 18 and over with completely resected small cell lung cancer that have had no prior systemic therapies for small cell lung cancer. Most cases of small cell lung cancer are not operable, but if they are, current treatment is a few months of chemotherapy. There have been many breakthroughs in more advanced cases of small cell, and this study seeks to bring those new approaches to earlier stage, more treatable cases of small cell lung cancer. The purpose of this study is to determine whether the addition of durvalumab to adjuvant chemotherapy (after surgical removal of small cell lung cancer) leads to improved disease-free survival. Durvalumab is a form of immune therapy, that enhances your own body’s defenses against cancer. It has been used in other forms of cancer treatments, including lung cancer, for several years. In this study, you will get chemotherapy and durvalumab every 3 weeks for 4 study treatments, followed by durvalumab alone once every 4 weeks for up to 9 study treatments, for a total of about 1 year of study treatment. All participants get the treatment; there is no “placebo” group. There will also be some tests done to evaluate what effect you may have from these study treatments and also to monitor any side effects you may experience during the course of the study. Most common side effects for Durvalumab: ? Fatigue (tiredness) ? Endocrine problems (for example, affecting function of the thyroid, kidney, pituitary gland, pancreas, or adrenal glands ? Dry skin ? Arthritis ? Diarrhea ? Inflammation of your lungs There may be some risks that the study doctors do not yet know about. You may or may not benefit as a result of your participation in this study. However, this study may also help doctors learn things that can help other people in the future. After you finish your study treatment, your study doctor will continue to follow your condition. For the study, the results of labs and scans will be collected for a maximum of 5 years from enrollment through review of your medical record, contact with your care provider(s), and/or telephone contact as needed every 3-4 months. Your care provider(s) may follow you beyond this per standard of care. Additional information found here: https://clinicaltrials.gov/study/NCT07149363?term=NCT07149363&rank=1 For questions, contact: [email protected]